Item no. |
CS-CRI172C |
Manufacturer |
Cell Sciences
|
Amount |
1.0 mg |
Category |
|
Type |
Proteins |
Specific against |
Human (Homo sapiens) |
Host |
E.coli |
Purity |
>97% by SDS-PAGE and HPLC analyses |
Sequence |
QGQDRHMIRM RQLIDIVDQL KNYVNDLVPE FLPAPEDVET NCEWSAFSCF QKAQLKSANT GNNERIINVS IKKLKRKPPS TNAGRRQKHR LTCPSCDSYE KKPPKEFLER FKSLLQKMIH QHLSSRTHGS EDS |
ECLASS 10.1 |
32160409 |
ECLASS 11.0 |
32160409 |
UNSPSC |
12352202 |
Similar products |
IL-21, Za11, interleukin-21 isoform, interleukin-21 |
Available |
|
Biological Activity |
Fully biologically active when compared to standard. The ED50 determined by a cell proliferation assay using human peripheral blood mononuclear cells is <10 ng/ml. |
Description |
IL-21 is a pleiotropic cytokine produced by CD4+ T cells in response to antigenic stimulation. Its action generally enhances antigen-specific responses of immune cells. The biological effects of IL-21 include induction of differentiation of T-cells-stimulated B-cells into plasma cells and memory B-cells, stimulation (in con-juction) with IL-4 of IgG production, and induction of apoptotic effects in naïve B-cells and stimulated B-cells in the absence of T-cell signaling. Additionally, IL-21 promotes the anti-tumor activity of CD8+ T-cells and NK cells. IL-21 exerts its effect through binding to a specific type I cytokine receptor, IL-21R, which also contains the gamma chain (γ, c) found in other cytokine receptors including IL-2, IL-4, IL-7, IL-9 and IL-15. The IL-21/IL-21R interaction triggers a cascade of events which includes activation of the tyrosine kinases JAK1 and JAK3, followed by activation of the transcription factors STAT1 and STAT3. Recombinant Human Interleukin-21 is a single, non-glycosylated polypeptide chain containing 133 amino acids. |
Endotoxin Level |
<1 EU/ug as determined by LAL method |
Formulation |
Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4. |
Molecular Weight |
ca.15.4 kDa |
Reconstitution |
Centrifuge vial prior to opening. Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/ml. Further dilutions should be made in appropriate buffered solutions. |
Storage and Stability |
The lyophilized protein is stable at 2-8C. Upon receipt, store desiccated at -20C. After reconstitution, the preparation is stable for up to one week at 2-8C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -80C. For long term storage of reconstituted protein, it is recommended that a carrier protein such as 0.1% BSA or HSA be added. This depends on the particular application. Avoid repeated freeze/thaw cycles. |
Specificity |
1.0 x 10E5 IU/mg. |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.